WorldHeart to gain Can$13 million financing:
This article was originally published in Clinica
WorldHeart is expecting to secure Can$13.3m ($10.3m) from the sale of unsecured convertible debentures and warrants through a private placement. The Ottawa, Ontario-based company is undergoing a restructuring of its manufacturing operations, having recently announced the consolidation of its Ottawa factory into its facilities in Oakland, California (see Clinica No 1123, p 13).
You may also be interested in...
The companies think they can build out the indications for zuranalone and SAGE-324 faster and more broadly and commercialize the drugs more effectively as partners.
The guidance document allows manufacturers to promote their dry-heat systems for mask bioburden reduction if they meet certain standards.
The US Medicare agency is letting ambulatory surgical centers and patient homes be reimbursed as in-patient hospitals for patient care purposes during the pandemic.